Warfarin versus direct oral anticoagulants in South Asian octogenarians: a retrospective review

• Published in: Blood coagulation & fibrinolysis Vol. 34; no. 5; p. 319
• Main Authors: Ee, Samuel Cheng En, Rosario, Barbara Helen, Mok, Zi Huan, Tun, Mon Hnin, Razali, Siti Shafia Bte Yang, Tan, Boon Hian
• Format: Journal Article
• Language: English
• Published: England 01.07.2023
• Subjects: Administration, Oral; Aged, 80 and over; Anticoagulants - adverse effects; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Embolism; Gastrointestinal Hemorrhage - drug therapy; Humans; Octogenarians; Retrospective Studies; Stroke - drug therapy; Warfarin - adverse effects
• ISSN: 1473-5733
• DOI: 10.1097/MBC.0000000000001233

To investigate the efficacy and safety outcomes of warfarin and direct oral anticoagulants in Asian octogenarians. A retrospective study was undertaken in 270 patients aged 80 years old and above, between 15 July 2015 and 21 December 2017, prescribed oral anticoagulation (OAC) with warfarin or direct oral anticoagulant (DOAC). Data collection included demographics, bleeding events, cessation of anticoagulation, mortality and hospital utilization up to 2 years post prescription. Thrombotic and embolic events within 30 days of anticoagulation cessation were reviewed. Data was analysed according to initial prescription of either warfarin or DOAC. There were 134 patients on warfarin and 136 patients on DOAC, of which majority of them were on anticoagulation for atrial fibrillation. In the warfarin group, there was a higher rate of minor bleeding events leading to permanent cessation (12.7 vs. 2.9%, P  = 0.035) compared with DOAC. Mortality rate at 2 years was higher in the warfarin group than DOAC (40.3 vs. 28.7%, P  = 0.044). There was no difference in major bleeding events, risk of gastrointestinal bleed or ICH between the two groups. There was no difference in rate of thrombotic and embolic events after cessation of anticoagulation and hospital utilization over 2 years was similar in both groups. In Asian octogenarians on anticoagulation, DOAC appears to have benefit over warfarin in terms of minor bleeding risk and mortality.